July 2012

Ariad asks FDA for priority review of leukemia drug

  • Tue, 07/31/2012 - 3:58pm

On Monday, Ariad Pharmaceuticals Inc.

Medtronic researchers sugar coated bone graft results

  • Tue, 07/31/2012 - 12:30pm

In 1999, reports about a breakthrough bone graft product started a commotion when clinical trials went awry. 

FDA approves prescription fish oil

  • Mon, 07/30/2012 - 10:12am

Last Thursday, the FDA approved a prescription fish oil to treat severely elevated levels of triglycerides, an unhealthy fatty acid that can build up and cause heart attack, stroke, and peripheral

New tracking system may stunt prescription drug abuse

  • Fri, 07/27/2012 - 12:49pm

Yesterday, we told you about a group of doctors petitioning the FDA for stronger labels on potentially addictive prescription drugs.

Health professionals petition for limits on painkillers

  • Thu, 07/26/2012 - 3:30pm

A group of health care professionals want the Food and Drug Administration to change labeling directions on how painkillers should be prescribed in order to prevent abuse of the

Injection restores sight

  • Thu, 07/26/2012 - 2:59pm

A new study revealed that a chemical injection into the eye could help restore sight to patients with inherited or acquired blindness.

New drug may treat TBI, MS, Alzheimer's and others

  • Wed, 07/25/2012 - 2:43pm

A new class of drugs may hold the key to treating neurodegenerative diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis and

FDA: MS drug may cause seizures

  • Wed, 07/25/2012 - 1:06pm

On Monday, the FDA warned that multiple sclerosis drug dalfampridine (brand name: Ampyra) may cause seizures when starting the medication.

New drug trio treats TB

  • Tue, 07/24/2012 - 4:16pm

A two week study in South Africa demonstrated that a combination of drugs known as PA-824MZ was capable of wiping out a significant amount of harmful tuberculosis (TB) bacteria.

Anticipated Alzheimer's drug shows no benefits in trial

  • Tue, 07/24/2012 - 3:47pm

Results from a large clinical trial revealed that Alzheimer’s drug bapineuzumab failed to affect cognition or everyday functioning in Alzheimer’s patients with a genetic mutation.

Pages